SysLogic wins FDA approval for blood device; Mystery med tech tenant buys big in CA;

@FierceMedDev: Luminex re-ups assay deal with Merck KGaA. News | Follow @FierceMedDev

@DamianFierce: Cyberonics slides after CMS again rejects depression device for reimbursement. Article | Follow @DamianFierce

> Colorado's Lanx has launched its Timberline MPF spinal plate fixation system, the first modular anchored interbody device for lateral fusion. News

> SysLogic won FDA approval for iTrace, a device that uses radio frequency identification to track blood samples and prevent the release of unsuitable blood components. More

> Maryland startup BioElectronics pulled in $500,000 in working capital to amp up production of its consumer medical devices for pain treatment, surgical procedure and wound care. Item

> Spinal Elements has licensed patents to develop lateral spine access devices, allowing the company to work on minimally invasive surgical technologies. Release

> A mystery life sciences company worth up to $10 billion is moving into 97,700 square feet of R&D space in San Francisco, and the unnamed tenant could well be a local heavyweight like Illumina ($ILMN) or BioMarin. Article

> A former Covidien ($COV) employee has been charged with heisting hydrocodone tablets from a company plant in New York. Story

Biotech News

@FierceBiotech: GSK buys Okairos (Fierce 15 profile) for $325M, strengthens vaccines biz. Release | Follow @FierceBiotech

@JohnCFierce: Novo spearheads $175M financing to back Ophthotech's PhIII AMD study. News | Follow @JohnCFierce

@RyanMFierce: UPDATED: GlaxoSmithKline bags genetic vaccine developer Okairos for $325M. Article | Follow @RyanMFierce

@EmilyMFierce: University of Alabama begins Parkinson's biomarker study. Story | Follow @EmilyMFierce

> Alexandria lands anchor R&D tenant for San Francisco biotech cluster. Article

> GenVec seeks liquidation after gene therapy setbacks. Report

> Novo spearheads $175M financing to back Ophthotech's PhIII AMD study. More

> Sights set on Asia, Amgen sets up JV development deal with Astellas. News

Pharma News

@FiercePharma: More Indian hospitals eye anti-Ranbaxy policies, Business Standard reports. Some patients asking to switch. Report | Follow @FiercePharma

 @EricPFierce: U.S. arrests 2 Pakistani men for selling controlled substances via the Internet. Interpol tracks them to London. Story | Follow @EricPFierce

 @CarlyHFierce: First Ranbaxy, now Wockhardt - what is India to do about its manufacturing problems? Regulators unsure. More | Follow @CarlyHFierce

> Re-analyzed Avandia data shows no increased heart risks. Report

> Big Kahuna statins gobble up bigger share of cholesterol market. Story

> Amgen forges ahead in Japan with Astellas joint venture. News

Biomarkers News

> New CTC technology looks promising to track evolution of prostate cancer. Report

> Swedish team discovers protein common to aggressive bladder cancer. More

> Cenix to collaborate with Debiopharm on predictive biomarkers. Article

> Pancreatitis or cancer? Mayo Clinic says mutated gene points the way. Story

> Johns Hopkins: Two genes help predict postpartum depression risk. Item

Drug Delivery News

 @MichaelGFierce: Morphine delivery platform could diminish abuse potential. Item | Follow @MichaelGFierce

> Shape-shifting nanoparticles anchor to tumor cells, deliver drugs. Story

> New drug targets lock-and-key mechanism of prostate cancer growth. Article

> Covidien completes successful drug-coated balloon trial. More

> Inhalable chemo-carrying nanoparticles target lung cancer directly. Report